search
Back to results

Accelerating Gastrointestinal Recovery

Primary Purpose

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Alvimopan
Placebo
Sponsored by
Jamie N. Bakkum-Gamez
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Ovarian Cancer focused on measuring Ovary, Ovarian, Fallopian, Peritoneal, Cancer, Gynecological, Female

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion criteria:

  • Females at least 18 years of age
  • Have an American Society of Anesthesiologists (ASA) Score of I to III
  • Are consented for primary, interval, or secondary cytoreduction for ovarian, tubal, or peritoneal cancer
  • Are scheduled to have their nasogastric tube removed before the first postoperative dose of study medication
  • Are able to understand the study procedures, have agreed to participate in the study program, and have voluntarily provided informed consent

Exclusion criteria:

  • Females younger than 18 years of age
  • Known non-gynecologic malignancy presenting with similar signs/symptoms as ovarian, tubal, or peritoneal cancer.
  • Have taken more than 7 consecutive days of therapeutic doses of opioids immediately prior to surgery
  • Use illicit drugs or abuse alcohol
  • Have had a prior total colectomy, gastrectomy, gastric bypass, or have a functional colostomy or ileostomy
  • Have an ongoing history of short bowel syndrome, chronic constipation (≤3 spontaneous bowel movements per week) or chronic diarrhea
  • Have received radiation therapy to the abdomen or pelvis within 3 months of scheduled surgery
  • Have chemotherapy or radiation induced bowel dysfunction
  • Are pregnant (identified by a positive urine or serum pregnancy test) or lactating, or are not postmenopausal (no menses for at least 1 year) and are of childbearing potential and not using an accepted method of birth control (ie, surgical sterilization, intrauterine contraceptive device, oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam, or abstinence)
  • Have participated in another investigational drug or medical device study within 30 days of surgery or will be enrolled in another investigational drug or medical device study or any study in which active patient participation is required outside normal hospital data collection during the course of this study
  • Have clinically significant laboratory abnormalities at screening that would result in the cancellation of surgery
  • Have a diagnosis of severe hepatic insufficiency or end stage renal disease.
  • Have a history of previous surgeries, illness, or behavior that in the opinion of the investigator might confound the study results or pose additional risk in administering the study procedures
  • Are unable to understand the study procedures and are not able to voluntarily provided informed consent

Sites / Locations

  • Mayo Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Alvimopan

Placebo

Arm Description

Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days.

Perioperative administration of placebo, at same dosing interval as study drug.

Outcomes

Primary Outcome Measures

Postoperative Length of Hospital Stay
Length of stay = date/time of hospital dismissal - date/time of end of surgery

Secondary Outcome Measures

Postoperative Ileus Incidence
Ileus was defined as MD-diagnosed, return to nothing by mouth (NPO) status, or insertion of nasogastric tube for ileus.

Full Information

First Posted
October 7, 2012
Last Updated
August 30, 2016
Sponsor
Jamie N. Bakkum-Gamez
Collaborators
Cubist Pharmaceuticals LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT01704651
Brief Title
Accelerating Gastrointestinal Recovery
Official Title
Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
August 2015 (Actual)
Study Completion Date
October 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jamie N. Bakkum-Gamez
Collaborators
Cubist Pharmaceuticals LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to determine whether an oral perioperative medication (alvimopan--a selective mu antagonist) improves bowel recovery over placebo after surgery for ovarian cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Keywords
Ovary, Ovarian, Fallopian, Peritoneal, Cancer, Gynecological, Female

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
146 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Alvimopan
Arm Type
Experimental
Arm Description
Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Perioperative administration of placebo, at same dosing interval as study drug.
Intervention Type
Drug
Intervention Name(s)
Alvimopan
Other Intervention Name(s)
Entereg
Intervention Description
Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Perioperative administration of placebo, at same dosing interval as study drug.
Primary Outcome Measure Information:
Title
Postoperative Length of Hospital Stay
Description
Length of stay = date/time of hospital dismissal - date/time of end of surgery
Time Frame
Patients will be followed for the duration of their hospital stay, an expected average of 5 days
Secondary Outcome Measure Information:
Title
Postoperative Ileus Incidence
Description
Ileus was defined as MD-diagnosed, return to nothing by mouth (NPO) status, or insertion of nasogastric tube for ileus.
Time Frame
Patients will be followed for 30 days postop

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Females at least 18 years of age Have an American Society of Anesthesiologists (ASA) Score of I to III Are consented for primary, interval, or secondary cytoreduction for ovarian, tubal, or peritoneal cancer Are scheduled to have their nasogastric tube removed before the first postoperative dose of study medication Are able to understand the study procedures, have agreed to participate in the study program, and have voluntarily provided informed consent Exclusion criteria: Females younger than 18 years of age Known non-gynecologic malignancy presenting with similar signs/symptoms as ovarian, tubal, or peritoneal cancer. Have taken more than 7 consecutive days of therapeutic doses of opioids immediately prior to surgery Use illicit drugs or abuse alcohol Have had a prior total colectomy, gastrectomy, gastric bypass, or have a functional colostomy or ileostomy Have an ongoing history of short bowel syndrome, chronic constipation (≤3 spontaneous bowel movements per week) or chronic diarrhea Have received radiation therapy to the abdomen or pelvis within 3 months of scheduled surgery Have chemotherapy or radiation induced bowel dysfunction Are pregnant (identified by a positive urine or serum pregnancy test) or lactating, or are not postmenopausal (no menses for at least 1 year) and are of childbearing potential and not using an accepted method of birth control (ie, surgical sterilization, intrauterine contraceptive device, oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam, or abstinence) Have participated in another investigational drug or medical device study within 30 days of surgery or will be enrolled in another investigational drug or medical device study or any study in which active patient participation is required outside normal hospital data collection during the course of this study Have clinically significant laboratory abnormalities at screening that would result in the cancellation of surgery Have a diagnosis of severe hepatic insufficiency or end stage renal disease. Have a history of previous surgeries, illness, or behavior that in the opinion of the investigator might confound the study results or pose additional risk in administering the study procedures Are unable to understand the study procedures and are not able to voluntarily provided informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jamie Bakkum-Gamez, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Accelerating Gastrointestinal Recovery

We'll reach out to this number within 24 hrs